"Advanced lipid panel" sounds like the obvious upgrade — more numbers, more insight, more of everything. But more isn't automatically better, and some advanced panels bundle in markers whose evidence is thin. Here's the honest version: what an advanced panel actually adds over a standard one, which additions carry real weight, who genuinely benefits, and how to get the fuller picture from the results you may already have.
What each panel is designed to do
The two tests answer slightly different questions. A standard lipid panel is built to screen the general population and flag frank abnormalities. An advanced panel is built to characterize risk more precisely — especially the risk that a standard panel can under-state. Neither is "wrong"; they're tuned for different jobs.
If you'd like the plain-language tour of what those standard lines mean first, start with how to read your lipid panel. This article is about the step after that: deciding whether the extra numbers are worth adding.
The two additions that actually earn their place
Advanced panels can list a dozen extras, but two carry the strongest evidence and do most of the work. Everything else is secondary.
1. ApoB — the particle count
Standard LDL-C measures the cholesterol your LDL particles carry, not how many particles there are. ApoB counts the atherogenic particles directly, and when the two disagree — discordance — ApoB tracks risk more faithfully. That's why the ESC/EAS guidelines highlight it, particularly when triglycerides are high or metabolic syndrome is present. It's inexpensive, widely available, and for many people it's the single most useful number to add. More in the ApoB guide →
2. Lp(a) — the inherited risk
Lp(a) is a genetically determined particle that raises cardiovascular risk independently of the rest of your panel, and it's essentially never in a standard test. Because it's largely fixed for life, it only needs measuring once — which makes it one of the highest-value single tests you can do. If you have an unexplained family history of early heart disease, this is often the missing piece. More in the Lp(a) guide →
Not every "advanced" marker is equally proven. The evidence behind ApoB and Lp(a) is strong and guideline-backed; some other add-ons have weaker support and can add cost without adding clarity. A good advanced panel isn't the one with the most boxes ticked — it's the one that measures what changes the decision. More numbers you don't know how to read isn't more insight.
Who actually benefits from going advanced
An advanced panel isn't for everyone, and it isn't urgent for everyone. It's most worth it if one or more of these fits you:
- You have a family history of early heart disease that your standard numbers don't explain — the classic case for checking Lp(a) once.
- Your standard lipids look "normal" but your metabolic markers don't — higher triglycerides, lower HDL, or early insulin resistance, where LDL-C most often under-states particle burden.
- You're optimizing for the long game — you want to read your numbers against longevity-optimal targets, not just wait for something to be flagged. Why “normal” isn't the same as optimal →
- Your LDL-C and other markers seem to disagree, and you want the number (ApoB) that settles it.
If none of these apply and your standard panel is genuinely clean, there's no need to rush — though a one-time Lp(a) is reasonable for almost anyone, precisely because you only ever do it once.
You usually don't need to start over. In most cases the practical upgrade is small: ask your doctor to add an ApoB to your next blood draw, add a one-time Lp(a) if you've never had it, and then read the whole set — old and new — against optimal targets rather than population ranges. That last step, the interpretation, is where the numbers turn into a decision.
How to actually get it done
- Ask, don't assume. "Can we add ApoB and a one-time Lp(a)?" is a reasonable request at your next visit. For the logistics of ordering ApoB specifically, see how ApoB testing works.
- Prioritize the two that matter. If cost or access is limited, ApoB and Lp(a) are the additions to prioritize over more exotic markers.
- Interpret against optimal. Advanced numbers are only as useful as the targets you read them against — ask what fits your risk, not just whether you're "in range." See the full cardiovascular-longevity framework →
- Then discuss and retest. Bring the fuller picture to your physician, and repeat over time.
Have a standard panel — want the advanced read?
CardioIQ takes the lab results you already have — plus ApoB and Lp(a) if you've added them — and interprets the full set against longevity-optimal targets, in a physician-grade report built by a lipidologist.
See how a CardioIQ report works Not sure what your numbers mean yet? Normal cholesterol, still at risk? →References
- Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal. 2020;41(1):111–188. doi:10.1093/eurheartj/ehz455
- Mach F, Koskinas KC, Roeters van Lennep JE, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal. 2025;46(42):4359–4378. doi:10.1093/eurheartj/ehaf190
- Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: an EAS consensus statement. European Heart Journal. 2022.